Nebenwirkungen · Edurant
EDURANT 25 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 11
HOS-213968 · Präparat HOS-155234
Table 2: ADRs reported in antiretroviral treatment-naïve HIV-1 infected adult patients treated with Rilpivirine (pooled data from the week 96 analysis of the phase 3 ECHO and THRIVE trials) N=686 System Organ Class (SOC) Frequency Category ADRs (Rilpivirine + BR) Blood and lymphatic system common decreased white blood cell count disorders decreased haemoglobin decreased platelet count Immune system disorders uncommon immune reactivation syndrome Metabolism and nutrition very common increased total cholesterol (fasted) disorders increased LDL cholesterol (fasted) common decreased appetite increased triglycerides (fasted) Psychiatric disorders very common insomnia common abnormal dreams depression sleep disorders depressed mood Nervous system disorders very common headache dizziness common somnolence Gastrointestinal disorders very common nausea increased pancreatic amylase
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage 9e72ac2848fbbe27a760fb37ccc9d194a3eff6d5a3822111d9a0cb864dd44101 · Zeichen 1654–3480 im Abschnitt